Minami Kyoto Hospital, National Hospital Organization
Neurology
I am working on the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. I believe that one is to remove the cause and the other is to regenerate the nerves. It is now known that accumulation of some abnormal protein is common in neurodegenerative diseases. If we can remove these abnormal proteins, or prevent them from forming, we may be able to eliminate the cause of the disease. Mesenchymal stem cells, with their ability to repair nerves, in addition to their ability to alleviate inflammation and repair vascular endothelium, may hypothetically be able to remove or inhibit the production of abnormal proteins. We are keenly working on the treatment of neurodegenerative diseases with these mesenchymal stem cells.

Moderator of 1 Session

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE: 131-132

Presenter of 1 Presentation

REPEATED INFUSION OF AUTOLOGOUS ADIPOSE TISSUE-DERIVED STEM CELLS FOR MULTIPLE SYSTEM ATROPHY

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE: 131-132
Lecture Time
09:30 AM - 09:45 AM

Abstract

Aims

Autologous adipose tissue-derived stem cells (ADSCs) have been shown to have the ability to repair nerve cells and myelin sheaths, have anti-inflammatory effects, and improve blood flow, as well as the potential to degrade and remove insoluble proteins. We have confirmed the safety of repeated intravenous administration of ADSCs for Alzheimer's disease, Parkinson's disease, and ALS, and have experienced multiple cases of symptomatic improvements. We hypothesize that ADSCs treatment is effective for neurodegenerative diseases including MSA.

Methods

ADSCs were administered intravenously to eight patients with multiple system atrophy (MSA; MSA consisted of one MSA-p and seven MSA-c) six times approximately every month. Patients were evaluated by neurological findings, modified Rankin Scale (mRS), ALSFRS-R (ALS Functional Rating Scale), and interviews with themselves and their caregivers.

Results

No adverse reactions were observed. There was no deterioration in vital signs, no significant worsening of blood chemistry, and no evidence of Amyloid Related Imaging Abnormalities (ARIA) on MRI. The mRS and ALSFRS scores were maintained during the observation period, and three patients showed improvement in subjective symptoms, including less swelling, ability to handle a pen, and opening the cap of a plastic bottle.

Conclusions

Intravenous administration of ADSCs appears to be promising for MSA, as well as for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. In neurodegenerative diseases, abnormal protein deposits occur in the brain, which correlates with aging, and ADSCs may have a mechanism to prevent these deposits.

Hide